Amatsigroup acquires Disposable-Lab, a developer of injectable dosage forms

Published: 23-Jan-2017

European CDMO Amatsigroup has announced the acquisition of Disposable-Lab, a company specialising in injectable dosage forms

Disposable-Lab is a fast-growing French company providing single-use technology solutions for aseptic formulation and manufacturing needs for (bio)pharmaceutical customers.

Founded in 2008 in Martillac, Disposable-Lab is the first pharmaceutical facility specifically designed and built for single-use processes in aseptic conditions.

It has benefited from growing market demand for single-use solutions for aseptic production of technical and clinical batches.

Single-use isolators and disposable equipment support the development of targeted new therapies based on biological molecules (immunotherapy in oncology, vaccines) as well as non-conventional processes (sterile powder filling, gene therapy, active vaccines and very small batch sizes).

Disposable-Lab increases safety through the use of full disposable equipment in a closed system providing all the features for aseptic filling.

It affords industrial flexibility to pharmaceutical labs and biotechnology companies, allowing them to set up production lines located close to their R&D teams.

Using Pyrofree technology, the company is able to provide a wide range of apyrogenic sterile vials, ready to use and suitable for advanced technology in manufacturing processes for sterile drugs.

Disposable-Lab reported €2.2 million in revenue in 2016, with 15 employees. It won the Deloitte In Extenso Technology Fast 50 South West companies award in 2016.

Over 60% of the group’s turnover is generated from foreign customers (Europe, US, Asia).

Amatsigroup’s aims to extend its aseptic manufacturing solutions for Good Manufacturing Practices compliant environments and increase its overall manufacturing capacity for sterile clinical batches, further to a recent investment on a second manufacturing line at its Idron’s facility.

This will allow the production of very small-scale batches — dosages around a microliter.

As a Contract Development and Manufacturing Organisation (CDMO), Amatsigroup provides preclinical and clinical services for the development of human and veterinary drugs.

It says it already has a leading position in manufacturing for parenteral and sterile clinical batches. The company is hoping to exceed its €50 million revenue bar by 2017.

Parenteral administration encompasses intravenous, subcutaneous, intradermic and intramuscular routes of administration for drugs.

Chair of Amatsigroup lain Sainsot said: “This acquisition fits perfectly with our strategy of being recognised as a leader in the field of sterile clinical batches manufacturing, matching perfectly the pharmaceutical industry increasing needs.”

Jean-Pascal Zambaux, Founder of Disposable-Lab, added: “We are very proud to join forces with Amatsigroup, a key player in clinical batches supply to the pharmaceutical industry.

“By leveraging the close fit between our businesses and the expertise of our teams, we will be able to develop the best possible manufacturing process to meet our customers’ requirements.”

You may also like